Lancashire and South Cumbria
Formulary
Formulary
4 Central nervous system
This chapter of the formulary is under continual development, please let the team know if you have any comments about the contents: mlcsu.lscformulary@nhs.net.
For more information about the formulary development process, please see: https://www.lancsmmg.nhs.uk/lancashire-and-south-cumbria-icb-formulary-development/
04-08-01 Control of epilepsy
| Brivaracetam Briviact® |
|
Formulary
|
Tablets - all strengths Oral solution Category 3 - It is usually unecessary to ensure that patients are maintained on a specific manufacturer's product as therapeutic equivalence can be assumed |
 MHRA: Antiepileptic drugs: updated advice on switching between different manufacturers products |
|
| Cannabidiol Epidyolex® |
|
Formulary
|
Oral solution 100mg/mL |
|
NICE TA873: Cannabidiol for treating seizures caused by tuberous sclerosis complex |
|
| Fenfluramine Fintepla® |
|
Formulary
|
Oral solution 2.2 mg/mL |
|
NICE TA808: Fenfluramine for treating seizures associated with Dravet syndrome |
|
|
Links
- Childrens Epilepsy Workstream in Trent (CEWT)
- DVLA: Epilepsy and driving fact sheet
- FDA: Drug Safety Communication - Risk of Serious Skin Reactions (Mar13)
- MHRA Drug Safety Update April 2018: Valproate medicines (Epilim, Depakote): contraindicated in women and girls of childbearing potential unless conditions of Pregnancy Prevention Programme are met
- MHRA Drug SAfety Update April 2018: Valproate medicines (Epilim, Depakote): contraindicated in women and girls of childbearing potential unless conditions of Pregnancy Prevention Programme are met
- MHRA Drug Safety Update April 2018: Valproate medicines (Epilim, Depakote): contraindicated in women and girls of childbearing potential unless conditions of Pregnancy Prevention Programme are met
- MHRA Drug Safety Update April 2018: Valproate medicines (Epilim, Depakote): contraindicated in women and girls of childbearing potential unless conditions of Pregnancy Prevention Programme are met
- MHRA Drug Safety Update April 2018: Valproate medicines (Epilim„, Depakote): contraindicated in women and girls of childbearing potential unless conditions of Pregnancy Prevention Programme are met
- MHRA Drug Safety Update April 2019: Pregabalin (Lyrica), gabapentin (Neurontin) and risk of abuse and dependence: new scheduling requirements from 1 April
- MHRA Drug Safety Update April 2019: Valproate medicines and serious harms in pregnancy: new Annual Risk Acknowledgement Form and clinical guidance from professional bodies to support compliance with the Pregnancy Prevention Programme
- MHRA Drug Safety Update Aril 2022: Pregabalin (Lyrica): findings of safety study on risks during pregnancy
- MHRA Drug Safety Update Feb 2016: Valproate and of risk of abnormal pregnancy outcomes: new communication materials
- MHRA Drug Safety Update Feb 2021: Pregabalin (Lyrica): reports of severe respiratory depression
- MHRA Drug Safety Update Jan 2021: Antiepileptic drugs in pregnancy: updated advice following comprehensive safety review
- MHRA Drug Safety Update July 2022: Topiramate (Topamax): start of safety review triggered by a study reporting an increased risk of neurodevelopmental disabilities in children with prenatal exposure
- MHRA Drug Safety Update May 2018: https://www.gov.uk/drug-safety-update/valproate-medicines-epilim-depakote-pregnancy-prevention-programme-materials-online
- MHRA Drug Safety Update May 2018: Valproate medicines (Epilim, Depakote): Pregnancy Prevention Programme materials online
- MHRA Drug Safety Update May 2018: Valproate medicines (Epilim, Depakote): Pregnancy Prevention Programme materials online
- MHRA Drug Safety Update May 2018: Valproate medicines (Epilim, Depakote): Pregnancy Prevention Programme materials online
- MHRA Drug Safety Update Nov 2017: Antiepileptic drugs: updated advice on switching between different manufacturers products
- MHRA Drug Safety Update Oct 2017: Gabapentin (Neurontin): risk of severe respiratory depression
- MHRA Drug Safety Update September 2018: Valproate medicines (Epilim, Depakote): Pregnancy Prevention Programme materials online
- MHRA Drug Safety Update September 2018: Valproate Pregnancy Prevention Programme: actions required now from GPs, specialists, and dispensers
- MHRA Drug Safety Update September 2018: Valproate Pregnancy Prevention Programme: actions required now from GPs, specialists, and dispensers
- MHRA Drug Safety Update September 2018: Valproate Pregnancy Prevention Programme: actions required now from GPs, specialists, and dispensers
- MHRA Drug Safety Update: Valproate and of risk of abnormal pregnancy outcomes: new communication materials
- MHRA Drug Safety Update: Valproate and of risk of abnormal pregnancy outcomes: new communication materials
- MHRA Drug Safety Update: Valproate and of risk of abnormal pregnancy outcomes: new communication materials
- MHRA safety update on pigmentation July 2013
- MHRA: Antiepileptic drugs: updated advice on switching between different manufacturers products
- MHRA: Antiepileptic drugs: updated advice on switching between different manufacturers products
- MHRA: Gabapentin (Neurontin): risk of severe respiratory depression
- MHRA: Pregabalin (Lyrica): findings of safety study on risks during pregnancy
- MHRA: Pregabalin (Lyrica): reports of severe respiratory depression
- MHRA: Retigabine (Trobalt▼): indication restricted to last-line use and new monitoring requirements
- MHRA: Topiramate (Topamax): introduction of new safety measures, including a Pregnancy Prevention Programme
- MHRA: Topiramate (Topamax): start of safety review triggered by a study reporting an increased risk of neurodevelopmental disabilities in children with prenatal exposure
- MHRA: Valproate use in men: as a precaution, men and their partners should use effective contraception
- MHRA: Valproate use in men: as a precaution, men and their partners should use effective contraception
- MHRA: Valproate use in men: as a precaution, men and their partners should use effective contraception
- MHRA: Valproate use in men: as a precaution, men and their partners should use effective contraception
- NICE CG137: The epilepsies: the diagnosis and management of the epilepsies in adults and children in primary and secondary care
- NICE evidence summary
- NICE NG217: Epilepsies in children, young people and adults
- NICE NG217: Epilepsies in children, young people and adults
- NICE NG217: Epilepsies in children, young people and adults
- NICE TA232: Retigabine for the adjunctive treatment of adults with partial onset seizures in epilepsy with and without secondary generalisation
- NICE TA753: Cenobamate for treating focal onset seizures in epilepsy
- NICE TA753:Cenobamate for treating focal onset seizures in epilepsy
- NICE TA808: Fenfluramine for treating seizures associated with Dravet syndrome
- NICE TA808: Fenfluramine for treating seizures associated with Dravet syndrome
- NICE TA873 Cannabidiol for treating seizures caused by tuberous sclerosis complex
- NICE TA873: Cannabidiol for treating seizures caused by tuberous sclerosis complex
- UKMI Q&A: Why is there a limit on the dose and duration of use for carbamazepine suppositories?
UKMI suggested drug monitoring schedule- UKMI Suggestions for Drug Monitoring
- UKMI suggestions for drug monitoring
- UKMI suggestions for drug monitoring
UMI Q&A: Information on change of phenytoin capsules to tablets and vice versa